Mingde Ma - Publications

Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 24, 2025

Peripheral blood inflammatory indexes in breast cancer: A review.

Journal: Medicine

Published: December 05, 2023

A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.

Journal: MedComm

Published: April 10, 2023

JHDM1D-AS1-driven inhibition of miR-940 releases ARTN expression to induce breast carcinogenesis.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 19, 2022

The HIF-1/SNHG1/miR-199a-3p/TFAM axis explains tumor angiogenesis and metastasis under hypoxic conditions in breast cancer.

Journal: BioFactors (Oxford, England)

Published: June 06, 2020

LINC00096 Promotes the Proliferation and Invasion by Sponging miR-383-5p and Regulating RBM3 Expression in Triple-Negative Breast Cancer.

Journal: OncoTargets and therapy

Published: September 03, 2019

Retracted Article: Down-regulation of Rab10 inhibits hypoxia-induced invasion and EMT in thyroid cancer cells by targeting HIF-1α through the PI3K/Akt pathway.

Journal: RSC advances

Published: July 09, 2018

Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 20, 2017

Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 08, 2017